Stay updated on Comparing Ocrelizumab and Ofatumumab in MS Clinical Trial
Sign up to get notified when there's something new on the Comparing Ocrelizumab and Ofatumumab in MS Clinical Trial page.

Latest updates to the Comparing Ocrelizumab and Ofatumumab in MS Clinical Trial page
- Check5 days agoNo Change Detected
- Check12 days agoChange DetectedThe page’s Locations section was updated to add Maryland and Victoria as locations and reorganize the location blocks. The HHS Vulnerability Disclosure link was removed and the revision label updated to v3.3.3.SummaryDifference0.4%

- Check19 days agoNo Change Detected
- Check26 days agoNo Change Detected
- Check41 days agoChange Detected- The page revision was updated from v3.2.0 to v3.3.2. This update does not appear to alter study details or other user-facing content.SummaryDifference0.1%

- Check48 days agoChange DetectedDeletion of the general government funding status notice that warned about potential updates and directed users to cc.nih.gov and opm.gov for operating status updates. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.5%

- Check63 days agoChange DetectedThe update appears to be cosmetic UI/layout changes with no changes to the study's core details such as title, conditions, outcomes, or locations. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.5%

- Check91 days agoChange DetectedIntroducing version v3.2.0 and a government-operating-status notice; removing the older v3.1.0 reference.SummaryDifference4%

- Check98 days agoChange Detected- Updated version from v3.0.2 to v3.1.0. - No other content changes detected.SummaryDifference0.1%

Stay in the know with updates to Comparing Ocrelizumab and Ofatumumab in MS Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Comparing Ocrelizumab and Ofatumumab in MS Clinical Trial page.